Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial

• Published in: Nature communications Vol. 14; no. 1; pp. 3698 - 15
• Main Authors: Rodrigues, Manuel, Vanoni, Giulia, Loap, Pierre, Dubot, Coraline, Timperi, Eleonora, Minsat, Mathieu, Bazire, Louis, Durdux, Catherine, Fourchotte, Virginie, Laas, Enora, Pouget, Nicolas, Castel-Ajgal, Zahra, Marret, Gregoire, Lesage, Laetitia, Meseure, Didier, Vincent-Salomon, Anne, Lecompte, Lolita, Servant, Nicolas, Vacher, Sophie, Bieche, Ivan, Malhaire, Caroline, Huchet, Virginie, Champion, Laurence, Kamal, Maud, Amigorena, Sebastian, Lantz, Olivier, Chevrier, Marion, Romano, Emanuela
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 22.06.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 13/31; 13/51; 38; 45; 45/23; 631/67/580; 692/4028/67/1517/1371; 692/53/2423; Antigen presentation; Antigens; B7-H1 Antigen; Brachytherapy; Cancer; CD11c antigen; CD3 antigen; CD4 antigen; CD8 antigen; Cell death; Cervical cancer; Chemoradiotherapy; Chemotherapy; Female; Foxp3 protein; Health risks; Humanities and Social Sciences; Humans; Immunological tolerance; Immunotherapy; Lung Neoplasms - drug therapy; Lymphocytes; Lymphocytes T; Macrophages; Monoclonal antibodies; multidisciplinary; Myeloid cells; Nivolumab - therapeutic use; Patients; PD-1 protein; PD-L1 protein; Phagocytosis; Programmed Cell Death 1 Receptor; Radiation therapy; Response rates; Risk assessment; Science; Science (multidisciplinary); Survival; Targeted cancer therapy; Tumor cells; Tumors; Uterine Cervical Neoplasms - drug therapy

Concurrent chemoradiotherapy (CRT) with blockade of the PD-1 pathway may enhance immune-mediated tumor control through increased phagocytosis, cell death, and antigen presentation. The NiCOL phase 1 trial (NCT03298893) is designed to determine the safety/tolerance profile and the recommended phase-I...